SCHEMBL7591759

SCHEMBL7591759

CC(C)(C)C=CC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15940374 1.00
SCHEMBL7591758 1.00
SCHEMBL17356122 0.75
SCHEMBL13741840 0.71 ALDH1A1 (0.35)
SCHEMBL11719737 0.71
SCHEMBL30878516 0.69
SCHEMBL6871703 0.69
SCHEMBL22478684 0.69 ALDH1A1 (0.33)
SCHEMBL6555443 0.69
SCHEMBL15710638 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4322957-A1 METHODS FOR TREATING DRUG AND VACCINE INDUCED IMMUNE THROMBOCYTOPENIA BY ADMINISTERING SPECIFIC COMPOUNDS Principia Biopharma Inc. (US) 2024-02-21 EP claimed
US-20230158031-A1 Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-05-25 US claimed
WO-2022221527-A1 METHODS FOR TREATING DRUG AND VACCINE INDUCED IMMUNE THROMBOCYTOPENIA BY ADMINISTERING SPECIFIC COMPOUNDS PRINCIPIA BIOPHARMA, INC. (US) 2022-10-20 WO claimed
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed
US-20250276983-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2025-09-04 US disclosed
EP-4587126-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION Amphista Therapeutics Ltd (GB) 2025-07-23 EP disclosed
EP-4577549-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 Iambic Therapeutics, Inc. (US) 2025-07-02 EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 US disclosed
CN-115244055-B Pyrimidine five-membered ring derivative and application thereof 江苏先声药业有限公司 2024-09-03 CN disclosed
US-20240182494-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2024-06-06 US disclosed
WO-2024057021-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2024-03-21 WO disclosed
US-20140228358-A1 ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
EP-0663394-B1 Process for preparing 5-aminodihydropyrrole, intermediate thereof and process for preparing said intermediate SUMITOMO CHEMICAL CO (JP) 2002-11-13 EP disclosed
EP-0464736-B1 A process for producing 5-amino-4-halogeno-1H-pyrazole compounds FUJI PHOTO FILM CO LTD (JP) 1997-01-02 EP disclosed
US-5498725-A Process for preparing 5-aminodihydropyrrole intermediate thereof and process for preparing said intermediate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-03-12 US disclosed
EP-0663394-A1 Process for preparing 5-aminodihydropyrrole, intermediate thereof and process for preparing said intermediate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-07-19 EP disclosed
US-5122612-A PROCESS FOR PRODUCING 5-AMINO-4-HALOGENO-1H-PYRAZOLE COMPOUNDS FUJI PHOTO FILM CO., LTD. (JP) 1992-06-16 US disclosed
EP-0464736-A1 A process for producing 5-amino-4-halogeno-1H-pyrazole compounds Fuji Photo Film Co., Ltd. (JP) 1992-01-08 EP disclosed